|Series B, 1/11 ||$7M|
|Venture Round, 12/11 ||$1M|
Interface Biologics Inc. operates as a biomaterials company. The company develops and markets polymer technologies that are programmed at the nano level for the combination medical device marketplace. It improves the biocompatibility of existing medical implants and blood-contacting devices. Interface Biologics provides lead product applications, such as vascular access catheters, drug eluting stents, and peritoneal dialysis catheters. The company was founded in 2001 and is headquartered in Toronto, Canada.